Publications searcher

The science produced by our scientists is very important. In 2022, 1,629 papers were published in scientific journals with a global impact factor of over 15,000 points.

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.

PMID: 24744161
Journal: CANCER CHEMOTH PHARM
Year: 2014
Reference: Cancer Chemother Pharmacol. 2014 Jun;73(6):1205-15. doi: 10.1007/s00280-014-2457-1. Epub 2014 Apr 18.
Impact factor: 2.571
Publication type: Paper in international publication
Authors: Salazar, Ramon, Morales, Serafin, Gil-Martin, Marta, Aguirre, Elena, Oaknin, Ana, Garcia, Margarita, Callies, Sophie, Wickremsinhe, Enaksha R, Benhadji, Karim A, Llombart, Antonio et al.
DOI: 10.1007/s00280-014-2457-1

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID: 24652201
Journal: INVEST NEW DRUG
Year: 2014
Reference: Invest New Drugs. 2014 Aug;32(4):670-81. doi: 10.1007/s10637-014-0082-9. Epub 2014 Mar 21.
Impact factor: 2.927
Publication type: Paper in international publication
Authors: Brana, Irene, Siu, Lillian L, De Jonge, Maja J, Homji, Natasha, Mills, David, Di Tomaso, Emmanuelle, Sarr, Celine, Trandafir, Lucia, Massacesi, Cristian, Eskens, Ferry et al.
DOI: 10.1007/s10637-014-0082-9

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors.

PMID: 24496004
Journal: J THORAC ONCOL
Year: 2014
Reference: J Thorac Oncol. 2014 Mar;9(3):316-23. doi: 10.1097/JTO.0000000000000088.
Impact factor: 5.8
Publication type: Paper in international publication
Authors: Felip, Enriqueta, Martinez, Pablo, Janne, Pasi A, Cohen, Roger B, Laird, A Douglas, Mace, Sandrine, Engelman, Jeffrey A, Ruiz-Soto, Rodrigo, Rockich, Kevin, Xu, Jianbo et al.
DOI: 10.1097/JTO.0000000000000088

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

PMID: 24583798
Journal: CLIN CANCER RES
Year: 2014
Reference: Clin Cancer Res. 2014 May 1;20(9):2445-56. doi: 10.1158/1078-0432.CCR-13-2403. Epub 2014 Feb 28.
Impact factor: 8.193
Publication type: Paper in international publication
Authors: Papadopoulos, Kyriakos P, Tabernero, Josep, Markman, Ben, Patnaik, Amita, Tolcher, Anthony W, Baselga, Jose, Shi, Weiliang, Egile, Coumaran, Ruiz-Soto, Rodrigo, Laird, A Douglas et al.
DOI: 10.1158/1078-0432.CCR-13-2403

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

PMID: 25142843
Journal: ONCOLOGIST
Year: 2014
Reference: Oncologist. 2014 Sep;19(9):917-8. doi: 10.1634/theoncologist.2014-0072. Epub 2014 Aug 20.
Impact factor: 4.54
Publication type: Paper in international publication
Authors: Suarez, Cristina, Bellmunt, Joaquim, Pons, Francesc, Bonfill, Teresa, Beltran, Marta, Moya, Irene, Galtes, Susana, Albanell, Joan, Carles, Joan, Rodon, Jordi et al.
DOI: 10.1634/theoncologist.2014-0072

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

PMID: 24827126
Journal: ANN ONCOL
Year: 2014
Reference: Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.
Impact factor: 6.578
Publication type: Paper in international publication
Authors: Balmana, J, Tung, N M, Isakoff, S J, Grana, B, Ryan, P D, Saura, C, Lowe, E S, Frewer, P, Winer, E, Baselga, J et al.
DOI: 10.1093/annonc/mdu187

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.

PMID: 24470511
Journal: CLIN CANCER RES
Year: 2014
Reference: Clin Cancer Res. 2014 Apr 1;20(7):1935-45. doi: 10.1158/1078-0432.CCR-13-1070. Epub 2014 Jan 27.
Impact factor: 8.193
Publication type: Clinical Trials
Authors: Di Tomaso, Emmanuelle, Saura, Cristina, Bendell, Johanna, Jerusalem, Guy, Su, Shaun, Ru, Qinhua, De Buck, Stefan, Mills, David, Ruquet, Sophie, Bosch, Ana et al.
DOI: 10.1158/1078-0432.CCR-13-1070

Phase II clinical trial of PM00104 (Zalypsis((R))) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

PMID: 24570330
Journal: CANCER CHEMOTH PHARM
Year: 2014
Reference: Cancer Chemother Pharmacol. 2014 Apr;73(4):857-67. doi: 10.1007/s00280-014-2419-7. Epub 2014 Feb 26.
Impact factor: 2.571
Publication type: Paper in international publication
Authors: Siguero, Mariano, Castellano, Daniel E, Bellmunt, Joaquim, Maroto, Jose Pablo, Font-Pous, Albert, Morales-Barrera, Rafael, Ghanem, Ismael, Suarez, Cristina, Martin Lorente, Cristina, Etxaniz, Olatz et al.
DOI: 10.1007/s00280-014-2419-7

Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke.

PMID: 25270629
Journal: STROKE
Year: 2014
Reference: Stroke. 2014 Nov;45(11):3304-10. doi: 10.1161/STROKEAHA.114.005835. Epub 2014 Sep 30.
Impact factor: 6.018
Publication type: Clinical Trials
Authors: Urfer, Roman, Moebius, Hans J, Skoloudik, David, Santamarina, Estevo, Sato, Wakao, Mita, Shiro, Muir, Keith W et al.
DOI: 10.1161/STROKEAHA.114.005835

Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.

PMID: 24081577
Journal: ANN HEMATOL
Year: 2014
Reference: Ann Hematol. 2014 Jan;93(1):43-6. doi: 10.1007/s00277-013-1914-y. Epub 2013 Oct 1.
Impact factor: 2.396
Publication type: Clinical Trials
Authors: Martinez-Cuadron, David, Montesinos, Pau, Oriol, Albert, Salamero, Olga, Vidriales, Belen, Bergua, Juan, Herrera, Pilar, Vives, Susanna, Sanz, Jaime, Carpio, Cecilia et al.
DOI: 10.1007/s00277-013-1914-y

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

PMID: 24401928
Journal: ANN ONCOL
Year: 2014
Reference: Ann Oncol. 2014 Mar;25(3):592-8. doi: 10.1093/annonc/mdt543. Epub 2014 Jan 8.
Impact factor: 6.578
Publication type: Clinical Trials
Authors: Baselga, J, Manikhas, A, Cortes, J, Llombart, A, Roman, L, Semiglazov, V F, Byakhov, M, Lokanatha, D, Forenza, S, Goldfarb, R H et al.
DOI: 10.1093/annonc/mdt543

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

PMID: 25193991
Journal: ANN ONCOL
Year: 2014
Reference: Ann Oncol. 2014 Nov;25(11):2244-51. doi: 10.1093/annonc/mdu390. Epub 2014 Sep 5.
Impact factor: 6.578
Publication type: Clinical Trials
Authors: Robert, R, D'Incalci, M, Zucchetti, M, Camboni, M G, Tabernero, J, Saba, C, Dubois, F, Allen, A, Litten, J, Soria, J-C et al.
DOI: 10.1093/annonc/mdu390

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.

PMID: 24997153
Journal: HAEMATOLOGICA
Year: 2014
Reference: Haematologica. 2014 Oct;99(10):1632-7. doi: 10.3324/haematol.2014.105908. Epub 2014 Jul 4.
Impact factor: 5.868
Publication type: Clinical guide
Authors: Valcarcel, David, Jarque, Isidro, Jimenez, Santiago, Rovira, Montserrat, Lopez, Javier, Hernandez, Dolores, Vallejo, Carlos, Batlle, Montserrat, Vazquez, Lourdes, Solano, Carlos et al.
DOI: 10.3324/haematol.2014.105908

Physical counter-pressure manoeuvres in preventing syncopal recurrence in patients older than 40 years with recurrent neurally mediated syncope: a controlled study from the Third International Study on Syncope of Uncertain Etiology (ISSUE-3)dagger.

PMID: 24906609
Journal: EUROPACE
Year: 2014
Reference: Europace. 2014 Oct;16(10):1515-20. doi: 10.1093/europace/euu125. Epub 2014 Jun 6.
Impact factor: 3.05
Publication type: Paper in international publication
Authors: Moya, Angel, van Dijk, Nynke, Giuli, Silvia, D'Ippolito, Giorgia, Gentili, Alessandra, Sutton, Richard, Kus, Teresa, Vitale, Elena, Romeo, Cristina, Tomaino, Marco et al.
DOI: 10.1093/europace/euu125

Physical exercise and health.

PMID: 25172071
Journal: REVISTA ESPANOLA DE CARDIOLOGIA
Year: 2014
Reference: Rev Esp Cardiol (Engl Ed). 2014 Sep;67(9):748-53. doi: 10.1016/j.rec.2014.04.005. Epub 2014 Jul 4.
Impact factor: 3.342
Publication type: Paper in international publication
Authors: Cordero, Alberto, Masia, M Dolores, Galve, Enrique et al.
DOI: 10.1016/j.rec.2014.04.005

Physical well-being in postoperative period: a survey in patients, nurses and physicians.

PMID: 24720578
Journal: J CLIN NURS
Year: 2014
Reference: J Clin Nurs. 2014 May;23(9-10):1421-9. doi: 10.1111/jocn.12446. Epub 2013 Dec 20.
Impact factor: 1.233
Publication type: Paper in international publication
Authors: Andion, Oscar, Canellas, Montserrat, Banos, Josep-E et al.
DOI: 10.1111/jocn.12446

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.

PMID: 24029546
Journal: J NEUROL NEUROSUR PS
Year: 2014
Reference: J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):851-8. doi: 10.1136/jnnp-2013-306132. Epub 2013 Sep 12.
Impact factor: 5.58
Publication type: Clinical Trials
Authors: Taba, P, Filippi, Massimo, Rocca, Maria A, Galay, N, Weber, J, Franta, C, Lampi, C, Shotekov, P, Bozhinov, S, Deleva, N et al.
DOI: 10.1136/jnnp-2013-306132

Plasma ST2 Predicts Mortality in Patients With Acute Respiratory Distress Syndrome.

PMID: 24638340
Journal: CHEST
Year: 2014
Reference: Chest. 2014 Mar 1;145(3 Suppl):174A. doi: 10.1378/chest.1822406.
Impact factor: 7.132
Publication type: Paper in international publication
Authors: Garcia de Acilu, Marina, Roca, Oriol, Masclans, Joan Ramon, Ruano, Laura, Rello, Jordi et al.
DOI: 10.1378/chest.1822406

Pneumonia and lung ultrasound in the intensive care unit.

PMID: 24638338
Journal: CHEST
Year: 2014
Reference: Chest. 2014 Mar 1;145(3 Suppl):171A. doi: 10.1378/chest.1806646.
Impact factor: 7.132
Publication type: Paper in international publication
Authors: Parra, Ana, Perez, Purificacion, Serra, Joaquim, Roca, Oriol, Masclans, Joan Ramon, Rello, Jordi et al.
DOI: 10.1378/chest.1806646

Pneumonia in inmunocompetent patients: combination antibiotic therapy.

PMID: 24122034
Journal: MINERVA ANESTESIOL
Year: 2014
Reference: Minerva Anestesiol. 2014 Apr;80(4):495-503. Epub 2013 Oct 11.
Impact factor: 2.272
Publication type: Paper in international publication
Authors: Salva, S, Borgatta, B, Rello, J et al.
DOI:

PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C.

PMID: 24927606
Journal: ANN HEPATOL
Year: 2014
Reference: Ann Hepatol. 2014 Jul-Aug;13(4):356-63.
Impact factor: 2.193
Publication type: Paper in international publication
Authors: Ampuero, Javier, Del Campo, Jose A, Rojas, Lourdes, Garcia-Lozano, Jose R, Sola, Ricard, Andrade, Raul, Pons, Jose A, Navarro, Jose M, Calleja, Jose L, Buti, Maria et al.
DOI:

Polypharmacy in patients hospitalised for acute exacerbation of COPD.

PMID: 24833769
Journal: EUR RESPIR J
Year: 2014
Reference: Eur Respir J. 2014 Sep;44(3):791-4. doi: 10.1183/09031936.00014814. Epub 2014 May 15.
Impact factor: 7.125
Publication type: Letter or abstract
Authors: Diez-Manglano, Jesus, Barquero-Romero, Jose, Mena, Pedro Almagro, Recio-Iglesias, Jesus, Cabrera-Aguilar, Javier, Viu, Ramon Boixeda, Soriano, Joan B, Lopez-Garcia, Francisco et al.
DOI: 10.1183/09031936.00014814

Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.

PMID: 25119184
Journal: CANCER CHEMOTH PHARM
Year: 2014
Reference: Cancer Chemother Pharmacol. 2014 Oct;74(4):819-29. doi: 10.1007/s00280-014-2560-3. Epub 2014 Aug 14.
Impact factor: 2.571
Publication type: Paper in international publication
Authors: Wada, D Russell, Li, Hanbin, Cortes, Javier, McNally, Virginia, Ross, Graham, Visich, Jennifer, Lum, Bert, Jin, Jin, Li, Jing, Garg, Amit et al.
DOI: 10.1007/s00280-014-2560-3

Posaconazole versus benznidazole for chronic Chagas' disease.

PMID: 25184871
Journal: NEW ENGL J MED
Year: 2014
Reference: N Engl J Med. 2014 Sep 4;371(10):966. doi: 10.1056/NEJMc1407914.
Impact factor: 54.42
Publication type: Letter or abstract
Authors: Molina, Israel, Salvador, Fernando, Sanchez-Montalva, Adrian et al.
DOI: 10.1056/NEJMc1407914

Publications

Publications searcher

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors.

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.

Phase II clinical trial of PM00104 (Zalypsis((R))) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke.

Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.

Physical counter-pressure manoeuvres in preventing syncopal recurrence in patients older than 40 years with recurrent neurally mediated syncope: a controlled study from the Third International Study on Syncope of Uncertain Etiology (ISSUE-3)dagger.

Physical exercise and health.

Physical well-being in postoperative period: a survey in patients, nurses and physicians.

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.

Plasma ST2 Predicts Mortality in Patients With Acute Respiratory Distress Syndrome.

Pneumonia and lung ultrasound in the intensive care unit.

Pneumonia in inmunocompetent patients: combination antibiotic therapy.

PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C.

Polypharmacy in patients hospitalised for acute exacerbation of COPD.

Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.

Posaconazole versus benznidazole for chronic Chagas' disease.

Patronage:

Collaborating:

Accreditations:

Publications searcher

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors.

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.

Phase II clinical trial of PM00104 (Zalypsis((R))) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke.

Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.

Physical counter-pressure manoeuvres in preventing syncopal recurrence in patients older than 40 years with recurrent neurally mediated syncope: a controlled study from the Third International Study on Syncope of Uncertain Etiology (ISSUE-3)dagger.

Physical exercise and health.

Physical well-being in postoperative period: a survey in patients, nurses and physicians.

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.

Plasma ST2 Predicts Mortality in Patients With Acute Respiratory Distress Syndrome.

Pneumonia and lung ultrasound in the intensive care unit.

Pneumonia in inmunocompetent patients: combination antibiotic therapy.

PNPLA3 rs738409 causes steatosis according to viral &amp; IL28B genotypes in hepatitis C.

Polypharmacy in patients hospitalised for acute exacerbation of COPD.

Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.

Posaconazole versus benznidazole for chronic Chagas' disease.

PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C.